109 related articles for article (PubMed ID: 9789740)
21. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
[TBL] [Abstract][Full Text] [Related]
22. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
23. Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction.
Pillai B; Kannan KK; Bhat SV; Hosur MV
Acta Crystallogr D Biol Crystallogr; 2004 Mar; 60(Pt 3):594-6. PubMed ID: 14993705
[TBL] [Abstract][Full Text] [Related]
24. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.
Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J
Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300
[TBL] [Abstract][Full Text] [Related]
25. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.
Martin P; Vickrey JF; Proteasa G; Jimenez YL; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
Structure; 2005 Dec; 13(12):1887-95. PubMed ID: 16338417
[TBL] [Abstract][Full Text] [Related]
26. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
[TBL] [Abstract][Full Text] [Related]
28. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
[TBL] [Abstract][Full Text] [Related]
29. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
30. Convergent chemical synthesis and crystal structure of a 203 amino acid "covalent dimer" HIV-1 protease enzyme molecule.
Torbeev VY; Kent SB
Angew Chem Int Ed Engl; 2007; 46(10):1667-70. PubMed ID: 17397076
[No Abstract] [Full Text] [Related]
31. Computational titration analysis of a multiprotic HIV-1 protease-ligand complex.
Spyrakis F; Fornabaio M; Cozzini P; Mozzarelli A; Abraham DJ; Kellogg GE
J Am Chem Soc; 2004 Sep; 126(38):11764-5. PubMed ID: 15382890
[TBL] [Abstract][Full Text] [Related]
32. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility.
Zoete V; Michielin O; Karplus M
J Mol Biol; 2002 Jan; 315(1):21-52. PubMed ID: 11771964
[TBL] [Abstract][Full Text] [Related]
33. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA
Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations.
Badaya A; Sasidhar YU
Sci Rep; 2020 Mar; 10(1):5501. PubMed ID: 32218488
[TBL] [Abstract][Full Text] [Related]
35. Refining the multiple protein structure pharmacophore method: consistency across three independent HIV-1 protease models.
Meagher KL; Lerner MG; Carlson HA
J Med Chem; 2006 Jun; 49(12):3478-84. PubMed ID: 16759090
[TBL] [Abstract][Full Text] [Related]
36. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
[TBL] [Abstract][Full Text] [Related]
37. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.
Ala PJ; Huston EE; Klabe RM; Jadhav PK; Lam PY; Chang CH
Biochemistry; 1998 Oct; 37(43):15042-9. PubMed ID: 9790666
[TBL] [Abstract][Full Text] [Related]
38. 1.8A X-ray structure of C95M/C1095F double mutant of tethered HIV-1 protease dimer complexed with acetyl pepstatin.
Prashar V; Hosur MV
Biochem Biophys Res Commun; 2004 Oct; 323(4):1229-35. PubMed ID: 15451428
[TBL] [Abstract][Full Text] [Related]
39. Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3.
Heaslet H; Kutilek V; Morris GM; Lin YC; Elder JH; Torbett BE; Stout CD
J Mol Biol; 2006 Mar; 356(4):967-81. PubMed ID: 16403521
[TBL] [Abstract][Full Text] [Related]
40. Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors.
Brik A; Muldoon J; Lin YC; Elder JH; Goodsell DS; Olson AJ; Fokin VV; Sharpless KB; Wong CH
Chembiochem; 2003 Nov; 4(11):1246-8. PubMed ID: 14613121
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
